LGALS3 and breast cancer: In a mouse model of TN breast cancer, treatment with AC and ICRP reduced tumor volume, prolonged survival, increased the numbers of infiltrating and systemic CD8+ T cells, and decreased the numbers of tumor suppressor molecules such as galectin-3, PD-L1, and IL-10 [128].